Compare SPPL & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPPL | MIRA |
|---|---|---|
| Founded | 2016 | 2020 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.0M | 43.7M |
| IPO Year | 2022 | 2023 |
| Metric | SPPL | MIRA |
|---|---|---|
| Price | $3.59 | $0.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 75.0K |
| Earning Date | 04-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $0.90 |
| 52 Week High | $7.00 | $2.45 |
| Indicator | SPPL | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 51.18 | 47.65 |
| Support Level | $3.47 | $0.91 |
| Resistance Level | $4.20 | $1.01 |
| Average True Range (ATR) | 0.23 | 0.04 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 23.46 | 50.00 |
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software (Facilities management software). The majority of its revenue is generated from the Robots segment. The company has expanded its operations into Australia /New Zealand and may also enter or expand in other geographic markets such as Canada, Hong Kong, Japan, the Middle East, the United Kingdom, Europe and the United States.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.